Affymax Inc is primarily active in the biotechnology industry.

The main competitors of Affymax Inc in the market are other pharmaceutical companies specializing in the development and commercialization of innovative biopharmaceutical products. These competitors include but are not limited to Amgen Inc, Johnson & Johnson, Bristol-Myers Squibb, Novartis AG, and Roche Holding AG.

Affymax Inc is a biopharmaceutical company founded in 2000. It focused on developing innovative drugs for the treatment of serious and often life-threatening conditions. The company specialized in utilizing advanced technology and scientific expertise to target specific disease pathways. Affymax Inc was known for its research and development in the field of hematology and oncology. Over the years, it collaborated with various partners to advance its drug pipeline. However, in 2013, Affymax Inc faced a setback when it voluntarily recalled its only commercial product due to safety concerns. This event led to significant financial challenges, and the company eventually filed for bankruptcy.

Affymax Inc has achieved several significant milestones. One of its notable achievements was the development of OMONTYS® (peginesatide), an erythropoiesis-stimulating agent used for treating anemia in chronic kidney disease patients. OMONTYS® received approval from the US Food and Drug Administration (FDA) in 2012, making it the first new ESA to be approved in the United States in over a decade. Additionally, Affymax Inc successfully entered into a collaboration with Takeda Pharmaceutical Company Limited to commercialize OMONTYS® globally. These achievements demonstrate Affymax Inc's commitment to innovation and addressing unmet medical needs in the field of anemia treatment.

Affymax Inc primarily operates in the United States.

Affymax Inc is a leading biopharmaceutical company known for its commitment to innovation and patient care. The company's corporate philosophy revolves around creating breakthrough therapies to address unmet medical needs. With a focus on research and development, Affymax Inc aims to improve patient outcomes and enhance quality of life. The values underlying the company's operations include integrity, collaboration, and a patient-centric approach. By prioritizing scientific excellence and leveraging innovative technologies, Affymax Inc remains dedicated to delivering effective and safe treatments. Through its mission-driven approach, the company strives to make a meaningful impact on the healthcare industry and the lives of individuals it serves.

Converted at the current exchange rate, the Affymax share trades at 0,00 EUR (0,00 USD).

Affymax Inc. is a California-based biotechnology company specializing in the development and marketing of innovative therapeutics for the treatment of kidney diseases. The company was founded in 2001 and has since become a leading provider of medical solutions. Affymax's business model is based on the development and marketing of drugs for the treatment of anemia in patients with chronic kidney diseases. Anemia treatment is one of the largest unmet medical needs in patients with chronic kidney diseases, where the body's own erythropoietin decreases. Affymax has a comprehensive portfolio of therapeutic products, including OMONTYS® (Peginesatide), a long-acting synthetic erythropoietin receptor agonist used monthly to treat anemia in adult dialysis patients with chronic kidney disease. The company works closely with healthcare partners to ensure that its medications are effective and cost-effective, and meet the needs of patients. Affymax is also expanding its presence in Europe and Asia to expand its international market opportunities. In addition to anemia treatment, Affymax has also developed a portfolio of therapies for the treatment of kidney and metabolic diseases. These include products such as AF-219, a potent and selective antagonist of the P2X3 receptor for the treatment of chronic cough, and AF-399, a low molecular weight inhibitor of the sodium-glucose cotransporter 2 (SGLT2) for the treatment of type 2 diabetes. Affymax is heavily focused on advancing its research and development activities to develop innovative therapy options to improve the health and well-being of patients. The company invests heavily in clinical trials and collaborations with other companies and academics to bring innovative products to market. Overall, Affymax is a strong and diversified biotechnology company with a wide range of products and services tailored to the needs of patients with chronic kidney diseases. The company is well positioned to expand its international market share and maintain its leadership position in the industry.

Liikevaihtoa ei voida laskea Affymax:lle tällä hetkellä.

Voittoa ei voida laskea Affymax:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Affymax:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Affymax:lle tällä hetkellä.

Affymax:n Eulpool-laatuscore on 3/10.

Affymax:n ISIN on US00826A1097. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Affymax:n ticker on AFFY. Tämä pörssinoteeraus käytetään Affymax-osakkeiden kauppaan pörssissä.

Affymax maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Affymax kuuluu sektoriin '—'.

Saadaksesi viimeisen osingon Affymax:sta päivältä määrässä 0,05 USD, sinulla piti olla osake portfoliossasi ennen irtoamispäivää .

Viimeinen osinko maksettiin .

Affymax:n osingot jaetaan valuutassa USD.